Financial Performance - The company's operating revenue for 2024 was CNY 122,173,752.36, a decrease of 14.13% compared to the previous year[4] - Net profit attributable to shareholders was CNY 15,823,591.14, down 40.67% year-on-year[4] - The basic earnings per share decreased to CNY 0.37, a decline of 48.61% from the previous year[4] - Total assets at the end of the reporting period were CNY 251,855,204.31, a decrease of 5.73% from the beginning of the period[4] - The equity attributable to shareholders increased slightly by 0.34% to CNY 193,671,398.63[4] Revenue and Profit Decline - The decline in revenue was primarily due to reduced budgets from end customers in the pharmaceutical sector, universities, and research institutions[7] - The decrease in net profit was attributed to lower operating revenue, reduced VAT refunds, and a decline in government subsidies[7] - The company reported a decrease in net profit of CNY 1,084.78 million due to the factors mentioned above[7] Financial Reporting and Caution - The company emphasizes that the financial data is preliminary and subject to audit, urging investors to be cautious[8] - The final financial figures will be disclosed in the official 2024 annual report[8]
博迅生物(836504) - 2024 Q4 - 年度业绩